BPH Global Registry
Recruiting · NCT05543200
Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
At a glance
- Research payments reported, 2025
- $30,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 7,500
About the trial
- Sponsor
- Société Internationale d'Urologie
- Dates
- Started 2023-03-13; completion 2028-12
- Results posted
- Not yet
Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.
From ClinicalTrials.gov, last updated 2026-08-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Teleflex LLC reported $30,000 in research payments for this study in 2025 (1 payments).
Products named: Urolift
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Southern California $30,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.